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ABSTRACT
Introduction of interferon b-1b in the therapeutic strategy against Multiple Sclerosis has resulted in a great amelioration
of treatment in various terms. Relapse rates, delaying progression of the activity, improvement of imaging outcomes
as well as reduction of disease activity itself consist great achievements against a pathological condition that challenged
medical effectiveness throughout decades. Two recombinant human IFN-1a and an IFN-1b preparations have been
proved effected and well tolerated. We reviewed the most important literature concerning pharmacodynamics, medical
efficacy, tolerability and adverse effects of interferon-b usage. In parallel, despite the wide range of trials referring to
INF-b treatment, we tried to categorize results of main trials in order to present our conclusions systematically.
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INTRODUCTION

present our conclusions systematically.

Introduction of interferon b-1b in the therapeutic strategy
against Multiple Sclerosis has resulted in a great
amelioration of treatment in various terms. Relapse
rates, delaying progression of the activity, improvement
of imaging outcomes as well as reduction of disease
activity itself consist great achievements against a
pathological condition that challenged medical
effectiveness throughout decades. The most remarkable
benefits are related with the Relapsing-Remittable and
Secondary Progressive forms of the disease, totally
contributing to several hopeful conclusions concerning
our therapeutic options.

MATERIALS AND METHODS
There are two main studies concerning Interferon optimal
dosage that consist our main material: Evidence and
benefit trial. Their results were combined with others
originated by a wide variety of series, altogether being
the material of our study. All trials studied have been
published and characterized by a remarkable citation
impact.
Concerning evidence trial, this was designed to assess
both tolerability and efficacy of the 2 available IFN-b1a preparations, examining their impact by clinical and
5
imaging measures . Patients received IFN-b-1a using
different formulations by different routes (SC vs. IM),
using different doses (44 vs. 30 ?g) and different dosing
frequencies (TIW vs. QW).

Two recombinant human IFN-1a and an IFN-1b
preparations have been proved effected and well
(1-4)
tolerated . Although their effectiveness is not doubted
by our modern medical reality, there are still critical
questions concerning specifically their optimal dosage
and their relative efficacy and safety. Although this is
inevitably an issue that preoccupies a series of recent
publications, certainty of conclusions is still a chimera.

Relatively, the benefit study aims to provide long-term
data on the efficacy of high-dose (250 ?g), highfrequency IFN-b-1b in patients with an experience of
6
a clinical event . It is a Phase III Study which has a
placebo-controlled, randomized, double-blind, parallelgroup design finally achieving also to compare treatment
initiated after the first event vs. just after the diagnosis
of MS.

We reviewed the most important literature concerning
pharmacodynamics, medical efficacy, tolerability and
adverse effects of interferon-b usage. In parallel, despite
the wide range of trials referring to INF-b treatment,
we tried to categorize results of main trials in order to
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when compared to placebo,significantly increased time
to first and second relapse, number of relapse-free
patients and improved imaging parameters. However,
IFN-b-1a once weekly 22mg subcutaneously in a
secondary progressive MS has been proved not to effect
significantly brain MRI measurement, clinical activity
or brain atrophy progression.

RESULTS
INF-b-1b has been proved to have a beneficial effect
to therapy of relapse remitting multiple sclerosis. Trials
have indicated that two doses, 8 million international
units, MIU (250?g) or 1.6 MIU (50?g) given
subcutaneously every other day, when compared to
placebo, reduced significantly the number of relapsefree patients, the time to first relapse and ?RI activity,
even though there were no significant effects on ?DSS.
Furthermore, multicentre trials of INF-b-1b 8 MIU against
placebo, demonstrated a significant reduction of clinical
and imaging activity against Secondary Progressive
Multiple Sclerosis, but no significant efficacy against
the progression of this form.

Two great randomized trials have evaluated the
comparative efficacy between intramuscular INF-b-1a
vs. INF-b-1b (??COMIN trial) or subcutaneous INF-b1a (EVIDENCE trial). INCOMIN trial showed that INFb-1b was significantly better than intramuscular INFb-1a in decreasing annual relapse rate and significantly
ameliorated MRI measures and disability disorders.
EVIDENCE trial proved as well that subcutaneous INFb-1a 44 ?g ??W was significantly yet modestly more
effective than intramuscular INF-b-1a 30?g QW
treatment in clinical and imaging measures. Results of
these two great trials have been as in diagrams.

Relatively, IFN-b-1a (6 MIU) given intramuscularly,
tested against placebo in a 2-year study, reduced
significantly exacerbations of RRMS but did not improved
significantly new T2 lesion creation. INF-b-1a doses of
22 or 44 ?g given subcutaneously three times a week,
INCOMIN trial results

OUTCOMES
Relapse free, no. (%)
Odds ratio
(95% CI)
Time to first
relapse , 40th
percentile, mos
Hazard ratio
Annualized
relapse rate
Steroid courses
per patient per year

SC IFN-B1a
44 µg TIW*
(n = 339)

IM IFN-bla
30 µg QW
(n = 338)

P p

191 (56)

163 (48)

0.023

6.7

0.002

0.54

0.65.

0.033

0.19

0.28

0.009

1.5 (1.1-2.0)
13.5
0.70

EVIDENCE trial results (after 104 weeks)

60%

IFNb-1b
250 µg SC

40%
20%

51%

36%

0%
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concluding similar results. Significant reductions in time
to becoming wheelchair bound, relapse rate and new
11.
and enhancing lesions for the 6 initial months of study

However, other head to head open label studies did
not show statistically significant difference in clinical
efficacy between IFN beta products. The potential
comparative superiority of IFN beta forms still remains
controversial.

When IFN-b-1a given intramuscularly was tested against
placebo there were also remarkable outcomes. Patients
treated with IFN-b-1a were significantly likely to reach
the primary endpoint, length of time to progression of
disability. Although no significant observation of T2
brain lesion load was observed, reduction of
12.
exacerbations reached 18%

Efficacy of INF-beta is significantly affected by the
development of Neutralizing antibodies (Nabs).
Numerous studies indicate the formation of Nabs up
to 35% of patients treated with interferon b-1b and up
to 24% of patients receiving subcutaneous INF-b-1a.
Main bioavailability factors include action of MxA protein
which limits correspondence to therapy and expression
levels of IFN response genes IFI127, TRIM69 and
(7-9)
EPSTI1 .

Finally, about INF-b-1a given subcutaneously, a large
study included 560 patients with RRMS. Patients were
randomized to receive treatment with INF-b-1a, 6 MIU
or 12 MIU or placebo. In both treated groups, there
was a decrease in the number of exacerbations of
about 27% and 33% respectively while there was a
4
significant decrease in their severity . There was also
a significant reduction of new and enlarging T2 lesions
whereas a better response was shown to high doses
13
in patients with higher disability .

Subcutaneous use of interferon may cause skin reactions
and pain in the injection site. Menstrual cycle in women,
liver function and white blood cell levels may also be
(10)
affected . Except all common side effects, there have
been cases where the appearance of rare syndromes
such as lupus, systemic sclerosis, dermatomyositis
were reported. Besides, the potential correlation to
breast cancer should be seriously considered.

Above results indicate the contributing effect of Interferon
in treatment against MS. Combining these observations
with those of INCOMIN and EVIDENCE trial, we could
make firmer conclusions on the optimal dosing and
efficacy. It seems that INF-b-1b is slightly superior to
Inf-b-1a as well as the subcutaneous usage of INF-b1a is modestly yet significantly preferable to the
intramuscular one.

DISCUSSION
Efficacy of interferon in other analysis IFN-b-1b was
initially proved to be effective when examined in a
double-blind versus placebo controlled trial involving
372 patients with RRMS in USA 1993. The primary
outcome was the relapse rate as treatment with the
higher dose reduces the relapse rate by approximately
30% and improved proportion of patients who were
relapse free. It also reduced patients with relapses to
the half1. Although there were no significant effects
on EDSS, MRI activity was shown to be significantly
1
decreased .

What remains uncertain?
There is a great issue concerning the development of
Neutralizing Antibodies. Their appearance, even
depended on dosage, remains uncertain about its
clinical interest. What is more important is the ranged
percentages of Nab that are mentioned by the various
trials to be stimulated by Interferon-b usage.

A second trial was performed in SPMS patients also

Average
Follow-Up

Dose

Frequency

NAB %

IFN-b-1a (PRISMS)
IFN-b-1a
(EVIDENCE)
IFN-b-1b
(NA-SPMS)

2 years

22 mg SC

3 times a week

23.8

48 weeks

30 µg IM

Once weekly

2

3 years

160 µg/m2 SC

Every other day

32

IFN-b-1b (BENEFIT)

2 years

250 µg SC

Every other day

29.9

Agent (Study)
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Further, there are questions related to the exact definition
of a treatment failure, evaluation criteria, MRI activity
and patient selection. These are parameters that
obviously create limitations to make firm conclusions.
Probably, more specific criteria and consensus about
treatment evaluation should be developed in order to
determine a more objective evaluation of Interferon
treatment.

9.

10.
11.

CONCLUSION
The comparative advantage between interferon beta
products still remains controversial but their significant
contribution to therapy of MS is commonly accepted.
Even if bioavailability and correspondence factors are
accepted to be precise in a satisfying level, the
appearance of new rare side effects indicates the
essential research needed in order to increase tolerance.
Large prospective studies comparing the efficacy and
tolerability of various treatment strategies may offer
the key to open the gate of full understanding of
Interferon therapeutic prospective.

12.
13.
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